New oral drug HRS-9813 takes first step against scarred lungs
NCT ID NCT06821464
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This Phase 1 trial tests the safety and how the body handles HRS-9813, an experimental oral drug for idiopathic pulmonary fibrosis (a lung-scarring disease). Healthy volunteers aged 18-45 take multiple doses to measure side effects and drug levels in the blood. The study does not yet test if the drug works against fibrosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-9813
- What this could lead to
- If safe and effective, HRS-9813 could become a new oral treatment for idiopathic pulmonary fibrosis, a serious lung-scarring disease.
- What could go wrong
- This is an early Phase 1 trial in healthy people, not patients. It only tests safety and drug processing, not whether it works against fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS/PROGRESSIVE PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China